Why the study?
The agreement between LVEDDi and LVEDVi to define LV dilatation and their respective prognostic implications in heart failure were not established.
Does left ventricular dilatation defined by both LVEDDi and LVEDVi predict cardiovascular death or heart failure hospitalization in patients with heart failure and LVEF < 50%?
Does left ventricular dilatation defined by both LVEDDi and LVEDVi predict cardiovascular death or heart failure hospitalization in patients with heart failure and LVEF < 50%?
In patients with heart failure and LVEF < 50%, assessing both LVEDDi and LVEDVi by cardiac magnetic resonance improves risk stratification, as patients with both metrics increased have the worst clinical outcomes.
Answers are grounded in this paper and cite their sources.
Dual LV dilatation by CMR may refine risk stratification in HF with LVEF <50%; hypothesis-generating pending prospective validation.
AIMS: To assess the agreement between left ventricular end-diastolic diameter index (LVEDDi) and volume index (LVEDVi) to define LV dilatation and to investigate the respective prognostic implications in patients with heart failure (HF). METHODS AND RESULTS: Patients with HF symptoms and LV ejection fraction (LVEF) < 50% undergoing cardiac magnetic resonance were evaluated retrospectively. LV dilatation was defined as LVEDDi or LVEDVi above the upper normal limit according to published reference values. Patients were followed up for the combined endpoint of cardiovascular death or HF hospitalization during 5 years. A total of 564 patients (median age 64 years; 79% men) were included. LVEDDi had a modest correlation with LVEDVi (r = 0.682, P < 0.001). LV dilatation was noted in 84% of patients using LVEDVi-based definition and in 73% using LVEDDi-based definition, whereas 20% of patients displayed discordant definitions of LV dilatation. During a median follow-up of 2.8 years, patients with both dilated LVEDDi and LVEDVi had the highest cumulative event rate (HR 3.00, 95% CI 1.15-7.81, P = 0.024). Both LVEDDi and LVEDVi were independently associated with the primary outcome (hazard ratio 3.29, 95%, P < 0.001 and 2.8, P = 0.009; respectively). CONCLUSION: The majority of patients with HF and LVEF < 50% present both increased LVEDDi and LVEDVi whereas 20% show discordant linear and volumetric definitions of LV dilatation. Patients with increased LVEDDi and LVEDVi have the worst clinical outcomes suggesting that the assessment of these two metrics is needed for better risk stratification.
No takes yet. Share an insight, caveat, or question.
Kasa et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: